206 related articles for article (PubMed ID: 16409557)
1. SUMOylation substrates in neuronal intranuclear inclusion disease.
Takahashi-Fujigasaki J; Arai K; Funata N; Fujigasaki H
Neuropathol Appl Neurobiol; 2006 Feb; 32(1):92-100. PubMed ID: 16409557
[TBL] [Abstract][Full Text] [Related]
2. Neuronal intranuclear inclusion disease without polyglutamine inclusions in a child.
McFadden K; Hamilton RL; Insalaco SJ; Lavine L; Al-Mateen M; Wang G; Wiley CA
J Neuropathol Exp Neurol; 2005 Jun; 64(6):545-52. PubMed ID: 15977647
[TBL] [Abstract][Full Text] [Related]
3. Two populations of neuronal intranuclear inclusions in SCA7 differ in size and promyelocytic leukaemia protein content.
Takahashi J; Fujigasaki H; Zander C; El Hachimi KH; Stevanin G; Dürr A; Lebre AS; Yvert G; Trottier Y; de Thé H; Hauw JJ; Duyckaerts C; Brice A
Brain; 2002 Jul; 125(Pt 7):1534-43. PubMed ID: 12077003
[TBL] [Abstract][Full Text] [Related]
4. Promyelocytic leukemia protein is redistributed during the formation of intranuclear inclusions independent of polyglutamine expansion: an immunohistochemical study on Marinesco bodies.
Kumada S; Uchihara T; Hayashi M; Nakamura A; Kikuchi E; Mizutani T; Oda M
J Neuropathol Exp Neurol; 2002 Nov; 61(11):984-91. PubMed ID: 12430715
[TBL] [Abstract][Full Text] [Related]
5. SUMO-1 marks the nuclear inclusions in familial neuronal intranuclear inclusion disease.
Pountney DL; Huang Y; Burns RJ; Haan E; Thompson PD; Blumbergs PC; Gai WP
Exp Neurol; 2003 Nov; 184(1):436-46. PubMed ID: 14637113
[TBL] [Abstract][Full Text] [Related]
6. PML nuclear bodies and neuronal intranuclear inclusion in polyglutamine diseases.
Takahashi J; Fujigasaki H; Iwabuchi K; Bruni AC; Uchihara T; El Hachimi KH; Stevanin G; Dürr A; Lebre AS; Trottier Y; de Thé H; Tanaka J; Hauw JJ; Duyckaerts C; Brice A
Neurobiol Dis; 2003 Aug; 13(3):230-7. PubMed ID: 12901837
[TBL] [Abstract][Full Text] [Related]
7. Modification of nuclear PML protein by SUMO-1 regulates Fas-induced apoptosis in rheumatoid arthritis synovial fibroblasts.
Meinecke I; Cinski A; Baier A; Peters MA; Dankbar B; Wille A; Drynda A; Mendoza H; Gay RE; Hay RT; Ink B; Gay S; Pap T
Proc Natl Acad Sci U S A; 2007 Mar; 104(12):5073-8. PubMed ID: 17360386
[TBL] [Abstract][Full Text] [Related]
8. Promyelocytic leukemia nuclear bodies provide a scaffold for human polyomavirus JC replication and are disrupted after development of viral inclusions in progressive multifocal leukoencephalopathy.
Shishido-Hara Y; Higuchi K; Ohara S; Duyckaerts C; Hauw JJ; Uchihara T
J Neuropathol Exp Neurol; 2008 Apr; 67(4):299-308. PubMed ID: 18379438
[TBL] [Abstract][Full Text] [Related]
9. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation.
Tatham MH; Geoffroy MC; Shen L; Plechanovova A; Hattersley N; Jaffray EG; Palvimo JJ; Hay RT
Nat Cell Biol; 2008 May; 10(5):538-46. PubMed ID: 18408734
[TBL] [Abstract][Full Text] [Related]
10. Interaction between neuronal intranuclear inclusions and promyelocytic leukemia protein nuclear and coiled bodies in CAG repeat diseases.
Yamada M; Sato T; Shimohata T; Hayashi S; Igarashi S; Tsuji S; Takahashi H
Am J Pathol; 2001 Nov; 159(5):1785-95. PubMed ID: 11696439
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase 7 promotes PML sumoylation and is essential for PML nuclear body formation.
Gao C; Ho CC; Reineke E; Lam M; Cheng X; Stanya KJ; Liu Y; Chakraborty S; Shih HM; Kao HY
Mol Cell Biol; 2008 Sep; 28(18):5658-67. PubMed ID: 18625722
[TBL] [Abstract][Full Text] [Related]
12. Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3.
Fu C; Ahmed K; Ding H; Ding X; Lan J; Yang Z; Miao Y; Zhu Y; Shi Y; Zhu J; Huang H; Yao X
Oncogene; 2005 Aug; 24(35):5401-13. PubMed ID: 15940266
[TBL] [Abstract][Full Text] [Related]
13. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway.
Lallemand-Breitenbach V; Jeanne M; Benhenda S; Nasr R; Lei M; Peres L; Zhou J; Zhu J; Raught B; de Thé H
Nat Cell Biol; 2008 May; 10(5):547-55. PubMed ID: 18408733
[TBL] [Abstract][Full Text] [Related]
14. NSF, Unc-18-1, dynamin-1 and HSP90 are inclusion body components in neuronal intranuclear inclusion disease identified by anti-SUMO-1-immunocapture.
Pountney DL; Raftery MJ; Chegini F; Blumbergs PC; Gai WP
Acta Neuropathol; 2008 Dec; 116(6):603-14. PubMed ID: 18836734
[TBL] [Abstract][Full Text] [Related]
15. The PML-nuclear inclusion of human supraoptic neurons: a new compartment with SUMO-1- and ubiquitin-proteasome-associated domains.
Villagra NT; Navascues J; Casafont I; Val-Bernal JF; Lafarga M; Berciano MT
Neurobiol Dis; 2006 Jan; 21(1):181-93. PubMed ID: 16125395
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the SUMO1 and ubiquitin conjugation pathways during the inhibition of proteasome activity with evidence of SUMO1 recycling.
Bailey D; O'Hare P
Biochem J; 2005 Dec; 392(Pt 2):271-81. PubMed ID: 16117725
[TBL] [Abstract][Full Text] [Related]
17. Apoptin is modified by SUMO conjugation and targeted to promyelocytic leukemia protein nuclear bodies.
Janssen K; Hofmann TG; Jans DA; Hay RT; Schulze-Osthoff K; Fischer U
Oncogene; 2007 Mar; 26(11):1557-66. PubMed ID: 16924230
[TBL] [Abstract][Full Text] [Related]
18. Neuronal intranuclear inclusion disease in a horse.
Pumarola M; Vidal E; Trens JM; Serafín A; Marquez M; Ferrer I
Acta Neuropathol; 2005 Aug; 110(2):191-5. PubMed ID: 15971054
[TBL] [Abstract][Full Text] [Related]
19. MageA2 restrains cellular senescence by targeting the function of PMLIV/p53 axis at the PML-NBs.
Peche LY; Scolz M; Ladelfa MF; Monte M; Schneider C
Cell Death Differ; 2012 Jun; 19(6):926-36. PubMed ID: 22117195
[TBL] [Abstract][Full Text] [Related]
20. Interferon-induced antiviral Mx1 GTPase is associated with components of the SUMO-1 system and promyelocytic leukemia protein nuclear bodies.
Engelhardt OG; Ullrich E; Kochs G; Haller O
Exp Cell Res; 2001 Dec; 271(2):286-95. PubMed ID: 11716541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
